11.3 Theft, Significant Loss & Disposal of Controlled Substances

11.3 Theft, Significant Loss & Disposal of Controlled Substances

The loss, diversion, or destruction of controlled substances represents an area of intense regulatory oversight. Under federal law (21 CFR § 1301.76(b) and 21 CFR Part 1317) and Utah pharmacy regulations (Utah Admin. Code R156-17b and R156-37), registrants must comply with precise administrative procedures when controlled substances are stolen, significantly lost, or earmarked for destruction. Pharmacists must distinguish between criminal theft, unexplained significant losses, transit discrepancies, and routine accidental breakage, ensuring that reports are delivered to the proper authorities within strict statutory deadlines.

Candidates preparing for the Utah MPJE must master the timelines for DEA and DOPL notifications, the execution of DEA Form 106 and DEA Form 41, and the lawful mechanisms for reverse distribution under the Secure and Responsible Drug Disposal Act.

---

Theft or Significant Loss Reporting: The Two-Step DEA Framework

When a registrant discovers a theft or significant loss of controlled substances, federal law (21 CFR § 1301.76(b)) establishes a mandatory two-step reporting protocol:

Loading diagram...

Step 1: Initial Written Notification (Within 1 Business Day)

Under 21 CFR § 1301.76(b), the registrant must notify the local DEA Diversion Field Office (Utah is served by DEA's Rocky Mountain Field Division and its Salt Lake City office) in writing within ONE (1) BUSINESS DAY of discovery of any theft or significant loss:

• The initial notification may be submitted via letter, fax, or secure email transmission to the field office.
• The notification serves as an immediate regulatory alert, establishing that an investigation has commenced.
• The registrant does not need to know the final quantity or all contributing factors at this initial stage.

Step 2: Electronic DEA Form 106 (Within 45 Calendar Days)

Following the initial 1-business-day notification, the registrant must conduct a thorough internal investigation to reconcile physical counts, audit perpetual logs, and determine the exact extent of the loss:

• Electronic Filing: The registrant must file a complete and accurate DEA Form 106 (Report of Theft or Loss of Controlled Substances) through DEA's Diversion Control Division secure network application (21 CFR § 1301.76(b)).
• 45-Day Deadline: Under a DEA rule published in June 2023, DEA Form 106 is due within 45 days after discovery of the theft or loss (21 CFR § 1301.76(b)). The parallel rule for non-practitioners such as distributors says 45 calendar days (21 CFR § 1301.74(c)).
• Investigation Yielding No Loss: If the pharmacy's investigation reveals that no actual theft or significant loss occurred (e.g., an inventory discrepancy was resolved as an initial miscount or bookkeeping data entry error), no DEA Form 106 needs to be filed. DEA's Pharmacist's Manual strongly recommends notifying DEA in writing to resolve the initial report and explain why no Form 106 was filed. Clerical miscounts and inventory adjustments are not reported on Form 106.

---

Evaluating "Significant Loss"

Neither the federal Controlled Substances Act nor DEA's rules sets a numerical threshold for a "significant loss"; the registrant must use its judgment. Under 21 CFR § 1301.76(b), a registrant should consider, among others, these six factors:

1. Actual Quantity Lost in Relation to Business Type: A loss of 50 tablets of oxycodone is extraordinarily significant for a small retail pharmacy, whereas 50 tablets lost in a multi-million-unit wholesale distribution center might be evaluated differently.
2. Specific Controlled Substances Lost: The loss of high-potency Schedule II opioids (fentanyl, hydromorphone, oxycodone) or Schedule II stimulants (amphetamine, methylphenidate) carries substantially higher diversion significance than an equivalent quantity of Schedule V cough syrups.
3. Association with Specific Individuals: Whether the loss can be tied to specific pharmacy personnel, contract cleaners, temporary relief staff, or unique suspicious dispensing patterns.
4. Pattern of Repeated Losses: Multiple small, unexplained shortages occurring over weeks or months (e.g., 5 tablets missing every Friday) constitute a significant loss pattern indicating ongoing pilferage, even if each individual loss appears minor.
5. Diversion Likelihood: Whether the missing substances are popular street drugs subject to black market demand.
6. Local and Regional Trends: Whether the drug is currently targeted in burglaries, robberies, or illicit street sales within the local Utah community.

---

In-Transit Losses: Supplier vs. Purchaser Responsibility

When controlled substances are stolen or lost while being shipped from a manufacturer or wholesale distributor to a purchasing pharmacy, reporting responsibility is determined by the transfer of legal custody:

• Supplier Responsibility: Under 21 CFR § 1301.74(c), the supplier (distributor) is responsible for reporting in-transit thefts and losses by its agent or its common or contract carrier within 1 business day and filing DEA Form 106. DEA's Pharmacist's Manual applies this to any loss from a shipment the purchaser has not signed for or taken custody of.
• Purchaser Responsibility: The moment the pharmacist or authorized pharmacy agent inspects the shipping manifest, signs the courier delivery receipt, and accepts custody of the containers, transit is legally complete. If the purchaser subsequently discovers a loss after signing the receipt, the purchaser must report the loss to the DEA on Form 106.
• Central Fill Operations: When a central fill pharmacy contracts with a carrier to transport filled prescriptions to a retail pharmacy, the central fill pharmacy reports in-transit losses on DEA Form 106. When the retail pharmacy contracts with the carrier to retrieve them, the retail pharmacy reports (21 CFR § 1301.76(d)).

---

Utah State Notifications: DOPL & Law Enforcement

Utah's controlled substance rule adds state notice duties to the federal ones. Under R156-37-602(2), a licensee who has any theft (including diversion) or significant loss of controlled substances must immediately:

• file the appropriate forms with DEA, with a copy to DOPL, directed to the Investigation Bureau; and
• report the incident to the local law enforcement agency.

Related Utah requirements:

• Accountability. Failing to keep controls a prudent licensee would keep against diversion, theft, or shortage, or failing to account for shortages, is unprofessional conduct (R156-37-502(4)–(5)). The PIC must maintain effective controls against theft and diversion (R156-17b-603(3)(k)).
• Wholesalers. Class C wholesalers must report significant inventory discrepancies involving counterfeit or contraband drugs, and suspected criminal activity involving drug inventory, to DOPL (and to FDA and DEA as applicable) within three business days (R156-17b-615(15)(f)–(g)).
• Records. Keep controlled substance records, including theft and loss reports, five years (R156-37-602(3)), and keep hard copies of surrender and destruction reports (R156-17b-614a(14)). Disposal follows 21 CFR Part 1317, and disposal records are also kept five years (R156-37-606).

---

Controlled Substance Disposal & Destruction (21 CFR Part 1317)

Under the Secure and Responsible Drug Disposal Act of 2010 and 21 CFR Part 1317, controlled substances must be rendered non-retrievable to prevent diversion. Pharmacies possess two primary avenues for handling unwanted or unusable stock:

1. Reverse Distribution (The Primary Commercial Method)

A community or institutional pharmacy does not directly destroy controlled substances on site. Instead, unwanted, expired, adulterated, or recalled stocks are transferred to a DEA-registered reverse distributor:

• Schedule II Transfer: The reverse distributor acts as the purchaser and must issue a single-sheet DEA Form 222 (or CSOS equivalent) to the pharmacy. The pharmacy acts as the supplier and fulfills the order by shipping the Schedule II stock to the reverse distributor.
• Schedule III–V Transfer: Documented on an official commercial invoice detailing drug name, strength, dosage form, quantity, date, and registered names/addresses of both parties.
• Destruction Execution: The reverse distributor destroys the substances to a non-retrievable state and is responsible for the DEA Form 41 (Registrant Record of Controlled Substances Destroyed). The pharmacy does not use Form 41 to record the transfer; its Form 222 copy or distribution record is its record.

2. Accidental Breakage and Spillage (The DEA Form 41 Rule)

A critical distinction frequently tested on the MPJE is the difference between a loss and accidental breakage/spillage:

• Not a Theft or Loss: If a technician drops a 500 mL stock bottle of liquid oral morphine concentrate or knocks over an open container of oxycodone tablets onto a wet compounding floor, rendering the drug unsalvageable, this is legally classified as breakage or spillage, NOT a theft or loss.
• No DEA Form 106: Witnessed breakage or spillage does not require notification to DEA, and DEA says Form 106 should be used only for thefts and significant losses.
• Recoverable drug: If the drug is still recoverable, dispose of it like any other inventory (on-site destruction, a reverse distributor, or DEA assistance under 21 CFR § 1317.05).
• Non-recoverable drug on DEA Form 41: DEA's position is that non-recoverable breakage or spillage must be recorded on DEA Form 41, signed by two individuals who can testify that the breakage or spillage occurred, and kept in the pharmacy's files. Utah also requires a perpetual inventory of Schedule II drugs (R156-17b-605(6)), so the pharmacy reconciles the book balance.

---

Common MPJE Traps & Scenario Analysis

1. Spilled Narcotic Reporting Trap: An MPJE question describes a pharmacist dropping a glass bottle of liquid methadone that shatters and seeps into a sink drain. The question asks which form must be filed with the DEA within one business day. No Form 106 is filed. Non-recoverable spillage is recorded on DEA Form 41, signed by two witnesses, kept on file, and reconciled in the Schedule II perpetual inventory.
2. The 45-Day vs. 1-Day Distinction: Candidates often confuse the initial 1-business-day written notice with the final DEA Form 106. The initial notice is due within 1 business day; the detailed electronic Form 106 is due within 45 calendar days.
3. Reverse Distributor Form 222 Execution: When sending expired OxyContin to a reverse distributor, candidates mistakenly think the pharmacy issues a Form 222. In reverse distribution, the reverse distributor is the purchaser and issues the Form 222 to the pharmacy.
4. In-Transit Signing Trap: If a pharmacist signs the delivery driver's electronic clipboard before opening the tote, and then opens the tote to find three bottles of hydrocodone missing, the pharmacy must report the loss on Form 106 because custody was legally accepted upon signature.